These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:
Pipeline and key clinical candidates for these companies:
Arcturus Therapeutics is a late-stage clinical mRNA medicines and vaccines company whose pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for COVID-19 and Influenza, and other programs to potentially treat ornithine transcarbamylase, or OTC, deficiency, and cystic fibrosis, or CF. The company's partnered programs include glycogen storage disease type III and hepatitis B virus.
United Therapeutics focuses on the areas of lung disease and organ manufacturing. United's next-generation therapies are designed to address the unmet needs of patients living with conditions such as PAH, PH, and end-stage organ disease.
Ligand is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand’s Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology is a "validated and scalable" platform for recombinant protein production that is suited for complex, large-scale protein production "where traditional systems are not," the company states.
Novo Nordisk is a global healthcare company headquartered in Denmark. The company describes it purposes as "to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders."
G1 Therapeutics is a commercial-stage biopharmaceutical company whose first commercial product is COSELA, or trilaciclib. G1 is executing a tumor-agnostic development plan evaluating trilaciclib in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.
Recent news on these stocks:
November 3
Citi analyst Yigal Nochomovitz upgraded Arcturus Therapeutics to Buy from Neutral with a price target of $35, up from $22, telling investors that the company's strategic collaboration with CSL Seqirus, a part of CSL Limited (CSLLY), addresses "the majority of our concerns on the investment thesis that have kept us Neutral-rated." The deal economics "appear highly competitive with landmark mRNA vaccine transactions" and puts Arcturus' self-amplifying mRNA platform "on the global vaccine map," Nochomovitz said. In addition, Arcturus eliminated its financing overhang with the upfront and near-term development milestones, the analyst argued.
November 2
United Therapeutics reported Q3 earnings per share of $4.91 against a consensus of $3.89, and reported Q3 revenue of $516.0M against a consensus of $493.2M. "We are thrilled to report the highest quarterly revenue in our history," said CEO Martine Rothblatt. "On top of our historic performance, we continue to innovate with the recent launch of the pivotal TETON 2 study of Tyvaso in idiopathic pulmonary fibrosis, which adds to the four other registration studies we have underway." "We are extremely pleased to have achieved several commercial milestones in the third quarter, highlighted by Tyvaso becoming our first $1B annual run rate product," said COO Michael Benkowitz. "Tyvaso DPI has provided a catalyst to our growth trajectory and has us well positioned to achieve our goal of 6,000 patients on Tyvaso by the end of the year."
Novo Nordisk reported its nine-month earnings, stating, "Sales in North America Operations increased by 37% in Danish kroner (22% at CER), and sales in International Operations increased by 16% in Danish kroner (11% at CER). Sales within Diabetes and Obesity care increased by 29% in Danish kroner to DKK 113.2 billion (18% at CER), mainly driven by GLP-1 diabetes sales growth of 59% in Danish kroner (44% at CER). Rare disease sales increased by 8% measured in Danish kroner (2% at CER). Obesity care sales grew by 91% in Danish Kroner (75% at CER). Novo Nordisk expects to make all Wegovy(R) dose strengths available in the US towards the end of 2022." CEO Lars Fruergaard Jorgensen said: "We are very pleased with the sales growth in the first nine months of 2022 which has enabled us to raise the outlook for the full year. The growth is driven by increasing demand for GLP-1-based diabetes treatments, especially Ozempic. Within R&D, the encouraging phase 2 data with CagriSema in type 2 diabetes and the successful completion of the phase 3 programme for once-weekly insulin icodec support our aspiration of further raising the innovation bar for diabetes treatments."
G1 Therapeutics described safety data from the first 18 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate, or ADC, sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer, or TNBC. These initial data highlight the potential for trilaciclib to meaningfully reduce adverse events related to use of sacituzumab. “Though the data are preliminary, we are seeing encouraging and consistent reductions in the rate of adverse events related to use of sacituzumab govitecan-hziy when trilaciclib is administered prior to the ADC, relative to the previously published single agent safety profile of this ADC, including those related to myelosuppression," said Raj Malik, Chief Medical Officer.
November 1
Ligand Pharmaceuticals announced the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company. OmniAb will begin regular-way trading November 2, 2022 on NASDAQ under the stock ticker symbol “OABI.” Ligand continues to trade under the stock ticker symbol “LGND.”
About “Biotech Alert”
The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.
This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel's online financial news media ecosystem.
This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.
Arcturus Therapeutics
+1.57 (+7.12%)
United Therapeutics
+1.64 (+0.62%)
Ligand
-0.215 (-0.34%)
Novo Nordisk
-0.67 (-0.59%)
G1 Therapeutics
+0.26 (+3.28%)
CSL
-1.12 (-1.26%)
OmniAb
-0.095 (-3.66%)